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Abstract Recent reductions in healthcare funding in the United States has pressured clinical laboratories to

provide the same quality of diagnostic testing with fewer resources. Testing cascades have been developed to assist
in the diagnosis of various illnesses, which use fewer tests and subsequently reduce costs. However, the cost
effectiveness of a celiac disease (CD) testing cascade compared to a panel is currently unknown. Therefore, the
purpose of this study was to determine if a CD testing cascade was equivalent to a panel in identifying patients
deemed likely for CD, and to compare their cost effectiveness in a sample of symptomatic patients from Northeast
Tennessee. A retrospective analysis using a CD testing cascade was performed on 933 outpatient samples referred to
our laboratory from 2012 to 2017 with a request for a celiac disease serology panel. The seroprevalence of CD for
the panel and the cascade were the same in this population (1.82%, 95% binomial confidence interval: 1.06% to
2.90%). The total cost of the CD cascade was 268% less than the cost of the panel resulting in a savings of $44,705,
which translates to a savings of $47.92/patient. Based on these findings, we recommend utilization of the cascade to
identify patients with likely CD. In the future, creative use of novel testing strategies can have significant
contributions to healthcare reform and afford patients more cost-effective clinical diagnostic testing.
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1. Introduction
Celiac disease (CD) is an immune-mediated inflammatory
reaction to dietary gluten which results in injury to the
mucosa of the small intestine with a loss of absorptive surface
area [1,2]. The seroprevalence of CD in the general population
is between 0.8-1% [1,3,4] and is on the rise. Despite rising
diagnosis rates [1,4,5], CD remains underdiagnosed in the
United States [1]. Currently, the favored strategy for
increasing detection of CD is an active-case finding approach
involving serological testing of patients with symptoms
(e.g. abdominal pain, diarrhea, chronic fatigue) or conditions
(e.g. irritable bowel syndrome, Down syndrome, Turner
syndrome) closely associated with CD. Among adult patients
with chronic abdominal symptoms, tissue transglutaminase
(TTG IgA) and endomysial antibodies (EMA IgA) have
the highest accuracy for diagnosis of CD. In IgA deficient
patients, TTG IgG, EMA IgG or deamidated gliadin
peptides (DGP IgG) are measured to screen for possible
CD. Despite advancements in serological testing for
CD, small intestinal biopsy with histology remains the
gold-standard for diagnosing CD. Considering the invasiveness
and expense of intestinal biopsies, serological testing
cascades have been developed to identify patients who are
at a higher risk for CD.

Recent healthcare reform has led to the progressive
contraction of healthcare funding [6,7]. As a result,
clinical laboratories have been pressured “to do more with
less” to provide the same quality of diagnostic testing with
fewer resources. Historically, laboratories have used
testing cascades to assist in diagnosis of various illnesses,
which use fewer tests and subsequently reduce costs.
While use of cascades for various illnesses (e.g. bacterial
infections [8], hypercholesterolaemia [9], sepsis [10])
have been shown to save money, physicians often order a
testing panel consisting of multiple assays. Various testing
cascades currently exist for CD from national clinical
laboratories (Mayo medical laboratories, ARUP, LabCorp);
however, their cost effectiveness compared to a CD panel
is currently unknown. Therefore, the purpose of this study
was to determine if a CD testing cascade was equivalent to
a panel in identifying patients deemed likely for CD,
and to compare their cost effectiveness in a sample of
symptomatic patients from Northeast Tennessee.

2. Materials and Methods
2.1. Study Sample
The patient population consisted of 933 consecutive
outpatient samples (male=299, female=634, age=45.06 ±
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19.84) referred to our laboratory from January 1st, 2012 to
August 1st, 2017 with a request for a celiac serology panel
to be performed. Samples were analyzed at East Tennessee
State University (ETSU) Clinical Laboratories, Quillen
College of Medicine. The ETSU Institutional Review
Board (IRB) determined that the study did not meet the
definition of human subjects’ research and therefore did
not require IRB review and approval.

were compared to assess cost effectiveness. Analyses
were conducted using Microsoft Excel 2013 (Microsoft
Corporation, Redmond, WA, USA).

2.2. Laboratory Analyses
Immunoglobulin A testing was performed on an
automated chemistry analyzer (Beckman Coulter AU 480,
Bellport, NY) using the immunoturbidimetric IgA assay
(Kamiya Biomedical Company, Tukwila, WA). The CD
assays: TTG IgA, DGP IgA, TTG IgG, DGP IgG were
performed on a Phadia 250 Immunoassay Analyzer
(assays and analyzer purchased from Fisher Scientific,
Hampton, NH). The EMA IgA test was performed at
Laboratory Corporation of America (Burlington, NC).
The CD panel included the following assays: IgA, TTG
IgA, EMA IgA, DGP IgA, DGP IgG. In our subsequent
retrospective analysis we applied the results from the
panel to a cascade we developed based in principle on
Mayo clinical laboratories CD cascade (Figure 1). For the
CD cascade, samples with IgA≥7 mg/dL (n=933) were
applied to TTG IgA and were further grouped based on
the package insert reference ranges: TTG IgA>10U/mL,
positive; 7-10 U/mL, equivocal; <4U/mL, negative.
Patient samples with IgA <7 mg/dL were removed from
the analyses due to the small sample size (n=8).

2.3. Statistical Analyses
Prevalence rates for positive serology are expressed
as a percentage of the total number of patient samples with
95% binomial confidence intervals (CIs) based on the
criteria used by Katz et al., [4]. Namely, a positive TTG
IgA or equivocal TTG IgA with either positive EMA IgA
or DGP IgA were deemed likely for CD. Reimbursements
for the various tests were obtained from the 2017
Medicare Clinical Diagnostic Laboratory Fee Schedule for
Tennessee. Grand total cost for the CD panel and cascade

Figure 1. CD Testing Cascade with results

3. Results
Overall the seroprevalence of CD in this population of
patients from Northeast Tennessee was 1.82% (95% CI:
1.06% to 2.90%) with 17 of 933 positive samples. The CD
cascade successfully captured all patients deemed likely
for CD. The EMA IgA results for 1 patient sample were
positive with all other tests negative, thus this patient was
considered unlikely for CD. The seroprevalence of CD in
pediatric (<18yr, 2 of 99) and adult samples (>18yr, 15 of
834) was similar. Therefore, the results from both of these
groups were combined for further analyses. The total cost
of the CD cascade was 268% less than the cost of the
panel resulting in a savings of $44,705 (Table 1).
Furthermore, the panel cost $76.42/patient, whereas the
cascade cost $28.50/patient, resulting in a savings of
$47.92/patient.

Table 1. Cost analysis for CD panel vs. cascade
Panel

Cascade

Assay

Number of tests

*Cost/assay

Total Cost

Number of tests

*Cost/assay

Total Cost

IgA

933

$12.76

$11,905

933

$12.76

$11,905

IgA TTG

933

$15.71

$14,657

933

$15.71

$14,657

IgA DGP

933

$15.71

$14,657

1

$15.71

$15.71

IgG DGP

933

$15.71

$14,657

0

$15.71

$0.00

IgA EMA

933

$16.53

$15,422

1

$16.53

$16.53

Total Cost

$71,300

$26,595

*Cost/assay determined from 2017 Medicare Clinical Diagnostic Laboratory Fee Schedule for Tennessee.

4. Discussion
The purpose of this study was to determine if a CD
testing cascade was equivalent to a panel in identifying
patients deemed likely for CD, and to compare their cost
effectiveness in a sample of symptomatic patients from
Northeast Tennessee. Our results showed that the CD

cascade captured all patients with a high probability of CD
and did so at a much lower cost compared to the panel.
The seroprevalence of CD in the present study (1.82%)
was slightly greater than that reported for the general
population (0.8% to 1.0%) [1,3,4]. This is likely because
the present study only tested symptomatic patients.
Also, it is important to note that IgA deficient samples
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(<7 mg/dL) were not included in this analysis and may
have influenced the observed seroprevalence rate.
Recent reductions in healthcare funding has pressured
clinical laboratories to provide the same quality of
diagnostic testing with fewer resources. The findings from
the current study support the use of a CD cascade that
resulted in lower costs, but still captured all patients with a
high probability of CD. In support of our findings,
unpublished data from Mayo Clinical Laboratories also
determined that a CD cascade resulted in a savings of
$39,527 and a diagnosis rate of 87% compared to a
hospital-ordered panel over a 12-month period [11].
Cascades used for other illnesses have also been effective
at reducing costs while maintaining diagnosis rates. For
example, a family screening strategy for hypercholesterolemia
resulted in a cost savings of ~$13,638/case detected
compared to a universal screening method in the United
Kingdom [9]. To further illustrate the impact on
healthcare spending, if the current CD cascade was used
instead of the panel in 1,000 clinical laboratories across
the United States it would result in a cost savings of nearly
$40 million. Considering the rising CD diagnosis rates and
hospital discharges for celiac disease [1,12], reducing
healthcare spending through the use of cascades is
paramount. Future research should address the utility and
cost benefit of cascades compared to other panels used to
screen for relatively common diseases.

5. Conclusions
The seroprevalence of CD for the panel and the cascade
were the same (1.82%) in a sample of symptomatic
patients from Northeast Tennessee over a 4.5-year period.
However, the CD cascade resulted in a $47.92 savings/patient
compared to the panel. Based on these findings, we
recommend utilization of the cascade to identify patients
with likely CD. In the future, creative use of novel testing
strategies can have significant contributions to healthcare
reform and afford patients more cost-effective clinical
diagnostic testing.
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